Geron Corporation  

(Public, NASDAQ:GERN)   Watch this stock  
Find more results for GERN
3.78
0.00 (0.00%)
Pre-market: 3.66 -0.12 (-3.17%)
Mar 6, 8:56AM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 1.39 - 4.80
Open     -
Vol / Avg. 112,064.00/2.75M
Mkt cap 594.26M
P/E     -
Div/yield     -
EPS -0.25
Shares 157.21M
Beta 2.11
Inst. own 42%
May 20, 2015
Geron Corp Annual Shareholders Meeting (Estimated) - 8:00AM EDT - Add to calendar
Mar 3, 2015
Q4 & FY 2014 Geron Corp Earnings Call - Webcast
Mar 3, 2015
Q4 & FY 2014 Geron Corp Earnings Release
Feb 9, 2015
Geron Corp at Biotechnology Industry Organization CEO & Investor Conference
Dec 8, 2014
Geron Analyst and Investor Meeting - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -5968.12% -2991.35%
Operating margin -6191.88% -3036.48%
EBITD margin - -2897.58%
Return on average assets -26.09% -45.92%
Return on average equity -27.19% -52.79%
Employees 46 -
CDP Score - -

Address

SUITE 2070, 149 COMMONWEALTH DRIVE
MENLO PARK, CA 94025
United States - Map
+1-650-4737700 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Geron Corporation (Geron) is a clinical-stage biopharmaceutical company developing a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Telomerase is an enzyme that enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. Imetelstat is a specific inhibitor of telomerase. The Company operates in one segment, the discovery and development of therapeutic products for oncology. Geron focuses to develop imetelstat to treat one or more hematologic myeloid malignancies, such as myelofibrosis (MF), myelodysplastic syndromes (MDS), or acute myelogenous leukemia (AML). The Company generates its revenues from research support payments under collaboration agreements and milestones, royalties and other revenues from its licensing arrangements.

Officers and directors

Hoyoung Huh Ph.D Chairman of the Board
Age: 45
Bio & Compensation  - Reuters
John A. Scarlett M.D. President, Chief Executive Officer, Director
Age: 62
Bio & Compensation  - Reuters
Olivia K. Bloom Chief Financial Officer, Executive Vice President - Finance, Treasurer
Age: 44
Bio & Compensation  - Reuters
Stephen N. Rosenfield J.D. Executive Vice President, General Counsel and Corporate Secretary
Age: 63
Bio & Compensation  - Reuters
Andrew J. Grethlein Ph.D. Executive Vice President - Technical Operations
Age: 48
Bio & Compensation  - Reuters
Melissa A. Kelly Behrs Executive Vice President - Portfolio and Alliance Management
Age: 49
Bio & Compensation  - Reuters
Craig C. Parker Executive Vice President - Corporate Development and Scientific Affairs
Bio & Compensation  - Reuters
Susan M. Molineaux Ph.D. Director
Age: 60
Bio & Compensation  - Reuters
Daniel M. Bradbury Independent Director
Bio & Compensation  - Reuters
Karin Eastham CPA Independent Director
Age: 65
Bio & Compensation  - Reuters